Medical device maker Biocomposites has expanded its portfolio with the launch of SYNICEM preformed spacers for hips, knees and shoulders in the UK.

These spacers were successfully used in patients undergoing joint surgery in the country.

The antibiotic-loaded spacers have been developed to address the challenges that result from traditional intra-operative moulded and handmade spacers.

By maintaining articular space and assisting in infection treatment, the spacers help surgeons revise the hip, knee and shoulder.

Biocomposites’ launch of the spacers comes after the company acquired French-based medical device manufacturer Synimed last year.

Biocomposites CEO Michael Harris said: “I’m delighted that our acquisition of Synimed has enriched our portfolio of products that support surgeon’s managing and treating infection.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

“SYNICEM spacers already help many patients throughout the world and bringing them into the UK and wider Biocomposites network will ensure that more patients benefit.”

Designed to ensure consistency and structural uniformity, SYNICEM spacers offer a high local concentration of gentamicin and provide case-by-case flexibility, thereby saving surgeons time during their procedures.

Royal United Hospitals Bath NHS Foundation Trust consultant orthopaedic surgeon Rohit Dhawan said: “Biocomposites’ SYNICEM spacers are really useful for orthopaedic surgeons who deal with infections.

“Ready to use and available in a variety of sizes to fit different patient anatomies, they provide the flexibility to enable a swift procedure, leaving patients infection-free and able to resume their day-to-day activities.”

In July this year, Biocomposites purchased a minority interest in UK-based Renovos Biologics for an undisclosed sum.

Renovos developed a synthetic, biodegradable nanoclay carrier called RENOVITE, which aims to position several pharmaceutical drugs and biologics at the treatment site.

Biocomposites focuses on the development and commercialisation of infection management products for bone and soft tissue.

Located in Keele, the company operates globally in the US, Europe, Canada, Argentina, India and China.